University of California, San Diego Healthcare
University of California, San Diego Healthcare
San Diego, CA, United States
Dr. Morris is an academic pulmonary and critical care physician at the University of California, San Diego. His clinical practice and translational research focus on pulmonary embolism (PE) and he has been invited to lecture about PE regularly at the annual meetings of the American Thoracic Society the American College of Chest Physicians and the American College of Physicians. He was honored by the American College of Chest Physicians as the Distinguished Scholar in Thrombosis, the first such award given by the College. He was also awarded a Certificate of Achievement from The American Thoracic Society as their Clinical Expert in Pulmonary Embolism. He has been the sole or contributing author on PE-related chapters in three major pulmonary textbooks. He authored the clinical guidelines for PE diagnosis adopted by the California Thoracic Society. He wrote the section on Pulmonary Vascular Disease for two editions of the American College of Physicians Medical Knowledge and Self Assessment Program (MKSAP).
Dr. Morris has a longstanding research interest in the pathophysiology of thrombosis and thrombus resolution, and its effect on the outcome of PE. He developed and validated a test to measure the physiological effect of post-PE residual pulmonary artery obstruction on cardiopulmonary function during exercise. His NIH-funded research implicated abnormalities in the structure and function of fibrinogen in the etiology of some patients’ resistance to fibrinolysis, and in the development of CTEPH and chronic thrombotic venous disease.
Those who know Dr. Morris frequently remark that his stories are “fascinating” each time they hear them and that his jokes “never get old.” He is well aware that most people do not read this far into the biographies of speakers. He is willing to buy a drink for the first audience member in 2024 who tells him that they read the entire thing.
Disclosure information not submitted.
Session V: PEppering the Panel: Rapid Fire Perspectives (The McRosenfield Group)
Thursday, September 18, 2025
8:30 AM – 9:30 AM US Pacific Time
Session VI: Risk Stratification of Acute PE: Integrating the Latest Guidelines and Algorithms
Thursday, September 18, 2025
9:30 AM – 10:30 AM US Pacific Time
DEBATE: Intermediate High vs. Intermediate Low Doesn't Warrant a Change in Therapy
Thursday, September 18, 2025
10:00 AM – 10:10 AM US Pacific Time
Discussion, Questions & Answers
Thursday, September 18, 2025
10:10 AM – 10:30 AM US Pacific Time
Session XI: Post-PE Management
Friday, September 19, 2025
8:20 AM – 9:10 AM US Pacific Time
Virtual Demonstration: CPET After PE
Friday, September 19, 2025
8:50 AM – 9:10 AM US Pacific Time
Friday, September 19, 2025
11:00 AM – 11:50 AM US Pacific Time
How and Why Does the Acute become Chronic
Friday, September 19, 2025
11:00 AM – 11:10 AM US Pacific Time
Friday, September 19, 2025
2:10 PM – 3:10 PM US Pacific Time